Form 4: Supernus Pharmaceuticals CEO Receives Stock Grant
Insider Transaction (Form 4)
Jack A. Khattar, President, CEO and a Director of Supernus Pharmaceuticals, Inc., received 29,849 shares of common stock on July 29, 2026.
Summary
- Grant/award: acquired 29,849 Performance Share Unit on July 29, 2026; holds 29,849 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jack A. Khattar — Director, Officer (President, CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-29 | Grant/award | Performance Share Unit | 29,849 | — | — | 29,849 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-29 | Grant/award (29,849 shares) |
Keywords
insider transaction, Form 4, SUPN, SUPERNUS PHARMACEUTICALS, INC., neutral, Jack A. Khattar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.